Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience.
Rovesti G, Orsi G, Kalliopi A, Vivaldi C, Marisi G, Faloppi L, Foschi FG, Silvestris N, Pecora I, Aprile G, Molinaro E, Riggi L, Ulivi P, Canale M, Cucchetti A, Tamburini E, Ercolani G, Fornaro L, Andreone P, Zavattari P, Scartozzi M, Cascinu S, Casadei-Gardini A. Rovesti G, et al. Among authors: tamburini e. Gastrointest Tumors. 2019 Oct;6(3-4):92-107. doi: 10.1159/000502714. Epub 2019 Sep 12. Gastrointest Tumors. 2019. PMID: 31768353 Free PMC article.
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib.
Casadei Gardini A, Marisi G, Scarpi E, Scartozzi M, Faloppi L, Silvestris N, Masi G, Vivaldi C, Brunetti O, Tamberi S, Foschi FG, Tamburini E, Tenti E, Ricca Rosellini S, Ulivi P, Cascinu S, Nanni O, Frassineti GL. Casadei Gardini A, et al. Among authors: tamburini e. Expert Opin Pharmacother. 2015;16(18):2719-25. doi: 10.1517/14656566.2015.1102887. Epub 2015 Oct 29. Expert Opin Pharmacother. 2015. PMID: 26513009 Free article.
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study.
Casadei Gardini A, Foca F, Scartozzi M, Silvestris N, Tamburini E, Faloppi L, Brunetti O, Rudnas B, Pisconti S, Valgiusti M, Marisi G, Foschi FG, Ercolani G, Tassinari D, Cascinu S, Frassineti GL. Casadei Gardini A, et al. Among authors: tamburini e. Sci Rep. 2017 Feb 13;7:42499. doi: 10.1038/srep42499. Sci Rep. 2017. PMID: 28211921 Free PMC article.
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
Casadei Gardini A, Faloppi L, De Matteis S, Foschi FG, Silvestris N, Tovoli F, Palmieri V, Marisi G, Brunetti O, Vespasiani-Gentilucci U, Perrone G, Valgiusti M, Granato AM, Ercolani G, Negrini G, Tamburini E, Aprile G, Passardi A, Santini D, Cascinu S, Frassineti GL, Scartozzi M. Casadei Gardini A, et al. Among authors: tamburini e. Eur J Cancer. 2017 Nov;86:106-114. doi: 10.1016/j.ejca.2017.09.003. Epub 2017 Oct 3. Eur J Cancer. 2017. PMID: 28985579 Free article.
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol.
Gardini AC, Faloppi L, Aprile G, Brunetti O, Caparello C, Corbelli J, Chessa L, Bruno D, Ercolani G, Leonetti A, Stefano G, Farella N, Foschi FG, Lanzi A, Dadduzio V, Marisi G, Masi G, Negri FV, Pagan F, Santini D, Scarpi E, Silletta M, Silvestris N, Tamburini E, Tassinari D, Vivaldi C, Gentilucci UV, Zagonel V, Calvetti L, Cascinu S, Frassineti GL, Scartozzi M. Gardini AC, et al. Among authors: tamburini e. Tumori. 2018 Dec;104(6):476-479. doi: 10.5301/tj.5000704. Epub 2018 May 9. Tumori. 2018. PMID: 29739298 Free article.
Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma.
Canale M, Ulivi P, Foschi FG, Scarpi E, De Matteis S, Donati G, Ercolani G, Scartozzi M, Faloppi L, Passardi A, Tamburini E, Valgiusti M, Marisi G, Frassineti GL, Casadei Gardini A. Canale M, et al. Among authors: tamburini e. Crit Rev Oncol Hematol. 2018 Sep;129:44-53. doi: 10.1016/j.critrevonc.2018.06.017. Epub 2018 Jun 23. Crit Rev Oncol Hematol. 2018. PMID: 30097237 Free article. Review.
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials.
Casadei Gardini A, Puzzoni M, Montagnani F, Marisi G, Tamburini E, Cucchetti A, Solaini L, Foschi FG, Conti F, Ercolani G, Cascinu S, Scartozzi M. Casadei Gardini A, et al. Among authors: tamburini e. Onco Targets Ther. 2019 Apr 24;12:2981-2988. doi: 10.2147/OTT.S192572. eCollection 2019. Onco Targets Ther. 2019. PMID: 31118665 Free PMC article.
Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis.
Casadei-Gardini A, Vagheggini A, Gelsomino F, Spallanzani A, Ulivi P, Orsi G, Rovesti G, Andrikou K, Tamburini E, Scartozzi M, Cascinu S. Casadei-Gardini A, et al. Among authors: tamburini e. Clin Colorectal Cancer. 2020 Jun;19(2):82-90.e9. doi: 10.1016/j.clcc.2019.10.001. Epub 2020 Mar 17. Clin Colorectal Cancer. 2020. PMID: 32192883
The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled Analysis.
Gelsomino F, Casadei-Gardini A, Rossini D, Boccaccino A, Masi G, Cremolini C, Spallanzani A, Viola MG, Garajovà I, Salati M, Elia MT, Caputo F, Santini C, Falcone A, Cascinu S, Tamburini E. Gelsomino F, et al. Among authors: tamburini e. Cancers (Basel). 2020 Apr 21;12(4):1022. doi: 10.3390/cancers12041022. Cancers (Basel). 2020. PMID: 32326305 Free PMC article.
193 results